Tian Zhang, MD, MHS, FASCO (@TiansterZhang) ranks #10 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 46 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: PROTEUS, XmAb819, LITESPARK-011. CMS Open Payments lists $25,345 in 2025 general payments.
At a Glance
- 23 posts naming a trial in 2026
- 19 trials discussed by name
- GU Cancer: US #10, Global #15 · 46 physicians engaged
- Leading physician voice: #2 of 15 physicians on XmAb819; #2 of 11 physicians on PEPE
- CMS Open Payments lists $25,345 in 2025 general payments.
This Month
What Tian Zhang, MD, MHS, FASCO has posted in the last 30 days. Updated November 10, 2026.
@montypal w phase 1 data from XmAb819 ENPP3/CD3 bispecific in tx-refractory #kidneycancer — manageable CRS & promising responses dose dependent. ENPP3 very interesting target for RCC. @oncoalert #ESMO26 @myESMO https://t.co/Yur2ZjCBct
Starting day 3 @myesmo #ESMO26 w kidney/bladder orals! What a great lineup of trials & speakers — #LITESPARK012 w @DrChoueiri, #LITESPARK011 w @DrDanielHeng, #PEPE w @Iacovelli, phase 1 of XmAb819 w @montypal & AK112 ivonescimab w #JunGuo @oncoalert https://t.co/PQ1kKTxdrE
@DrIacovelli with phase 2 #PEPE trial - pembrolizumab w met directed treatment vs MDT in oligomet #kidneycancer — meets 1o PFS endpoint. Congrats on well done IIT. My practice is pembro after consolidative tx & great to see prospective supporting data. @oncoalert #ESMO26 @myESMO https://t.co/dgPrjmTb1Q
@DrChoueiri 1st up w #LITESPARK012 - Len/bel/pembro vs Len/quavonlimab/pembro vs Len/pembro for #kidneycancer. No diff in PFS or OS - likely from strong control cohort. Still no triplet for 1st line metastatic RCC. @oncoalert #ESMO26 @myESMO https://t.co/08j4zrxYuS
@AlbigesL with 1st deliverable for #CARE1 trial, PD-L1 stratified IO-IO vs IO-TKI in metastatic #kidneycancer. Local PD-L1 status correlated well w central review. Much more to come from this pragmatic trial! @oncoalert #ESMO26 @myESMO https://t.co/K2N2PMPjFt
@DrChoueiri w last, very last update of #Keynote564 pembrolizumab for adjuvant #kidneycancer. Ongoing overall survival benefit — even 7+ years out. @oncoalert #ESMO26 @myESMO https://t.co/RzNWvKHPuq
Who Amplifies Tian Zhang, MD, MHS, FASCO
Physicians who reposted Tian Zhang, MD, MHS, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #10 | #15 | 46 | 69 | Full ranking |
What Colleagues Are Saying About Tian Zhang, MD, MHS, FASCO
2026 posts by fellow physicians that mention @TiansterZhang, quoted word for word.
Many thanks to the @OncBrothers for allowing me to be a part of yet another terrific program at #ASCO26! Was thrilled to see my @cityofhope colleague @hoperugo after my panel w @TiansterZhang & @apolo_andrea. Bonus: Got to see the incredible @jhaveri_komal just before she graced the stage!
Trials Tian Zhang, MD, MHS, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| PROTEUS | 4 | #22 of 56 | Oct 24, 2026 |
| XmAb819 | 2 | #2 of 15 | Oct 25, 2026 |
| LITESPARK-011 | 2 | #8 of 37 | Oct 25, 2026 |
| LITESPARK-012 | 2 | #3 of 21 | Oct 25, 2026 |
| PEPE | 2 | #2 of 11 | Oct 25, 2026 |
| KEYNOTE-866 | 2 | #5 of 26 | Oct 23, 2026 |
| CARE1 | 1 | #6 of 6 | Oct 25, 2026 |
| KEYNOTE-564 | 1 | #13 of 16 | Oct 25, 2026 |
| JNJ-6143 | 1 | #4 of 16 | Oct 24, 2026 |
| PEACE-1 | 1 | #9 of 18 | Oct 24, 2026 |
| VOLGA | 1 | #21 of 57 | Oct 24, 2026 |
| DASL-HiCaP (ANZUP1801) | 1 | #15 of 28 | Oct 24, 2026 |
| DeLLphi-305 | 1 | #37 of 86 | Oct 24, 2026 |
| NIAGARA | 1 | #17 of 32 | Oct 23, 2026 |
| ENERGIZE (CA017-078) | 1 | #9 of 17 | Oct 23, 2026 |
| ARACOG | 1 | #5 of 10 | May 30, 2026 |
| TALAPRO-3 | 1 | #19 of 39 | May 30, 2026 |
| AMBASSADOR | 1 | #5 of 7 | May 29, 2026 |
| IMvigor011 | 1 | #17 of 20 | May 15, 2026 |
Tian Zhang, MD, MHS, FASCO on PROTEUS
#PROTEUS substudy of ADT-Apalutamide in high risk #prostate cancer w/ significantly positive event free survival. Salvage radiation rates half of those in control cohort. @oncoalert #esmo26 @myESMO
#MaryEllenTaplin @DanaFarber_GU with first plenary of the day @asco #ASCO26 — phase 3 of #PROTEUS — >2100 patients w high risk #prostatecancer, adt and apalutamide improved path CR and also a highly powered statistically significant MFS benefit. @oncoalert @urotoday @PCF_Science https://t.co/QeQYG6LiRy
@declangmurphy @PeterMacCC pushes limits of evolution of high risk #prostatecancer as we do space travel. MFS of #PROTEUS is positive &highly powered. Path CR high at 8.9%. May we keep pushing limits of #prostatecancer care. @asco #ASCO26 @OncoAlert @urotoday https://t.co/uCieW6FSOH
Tian Zhang, MD, MHS, FASCO on XmAb819
@montypal w phase 1 data from XmAb819 ENPP3/CD3 bispecific in tx-refractory #kidneycancer — manageable CRS & promising responses dose dependent. ENPP3 very interesting target for RCC. @oncoalert #ESMO26 @myESMO https://t.co/Yur2ZjCBct
Starting day 3 @myesmo #ESMO26 w kidney/bladder orals! What a great lineup of trials & speakers — #LITESPARK012 w @DrChoueiri, #LITESPARK011 w @DrDanielHeng, #PEPE w @Iacovelli, phase 1 of XmAb819 w @montypal & AK112 ivonescimab w #JunGuo @oncoalert https://t.co/PQ1kKTxdrE
Tian Zhang, MD, MHS, FASCO on LITESPARK-011
Starting day 3 @myesmo #ESMO26 w kidney/bladder orals! What a great lineup of trials & speakers — #LITESPARK012 w @DrChoueiri, #LITESPARK011 w @DrDanielHeng, #PEPE w @Iacovelli, phase 1 of XmAb819 w @montypal & AK112 ivonescimab w #JunGuo @oncoalert https://t.co/PQ1kKTxdrE
@DrDanielHeng w #LITESPARK011 follow-up — Lenvatinib-belzutifan vs cabozantinib met PFS endpoint and also better for PFS2, just misses on OS. Durable responses. Lenvatinib belzutifan approved in US — another line in the IO refractory setting. @oncoalert #ESMO26 @myesmo https://t.co/p8dOqHsP38
Tian Zhang, MD, MHS, FASCO on LITESPARK-012
Starting day 3 @myesmo #ESMO26 w kidney/bladder orals! What a great lineup of trials & speakers — #LITESPARK012 w @DrChoueiri, #LITESPARK011 w @DrDanielHeng, #PEPE w @Iacovelli, phase 1 of XmAb819 w @montypal & AK112 ivonescimab w #JunGuo @oncoalert https://t.co/PQ1kKTxdrE
@DrChoueiri 1st up w #LITESPARK012 - Len/bel/pembro vs Len/quavonlimab/pembro vs Len/pembro for #kidneycancer. No diff in PFS or OS - likely from strong control cohort. Still no triplet for 1st line metastatic RCC. @oncoalert #ESMO26 @myESMO https://t.co/08j4zrxYuS
Tian Zhang, MD, MHS, FASCO on PEPE
Starting day 3 @myesmo #ESMO26 w kidney/bladder orals! What a great lineup of trials & speakers — #LITESPARK012 w @DrChoueiri, #LITESPARK011 w @DrDanielHeng, #PEPE w @Iacovelli, phase 1 of XmAb819 w @montypal & AK112 ivonescimab w #JunGuo @oncoalert https://t.co/PQ1kKTxdrE
@DrIacovelli with phase 2 #PEPE trial - pembrolizumab w met directed treatment vs MDT in oligomet #kidneycancer — meets 1o PFS endpoint. Congrats on well done IIT. My practice is pembro after consolidative tx & great to see prospective supporting data. @oncoalert #ESMO26 @myESMO https://t.co/dgPrjmTb1Q
Tian Zhang, MD, MHS, FASCO on KEYNOTE-866
Nice comparison chart @tompowles1 — control cohorts in the #ENERGYZE & #Keynote866 trials both did much better than #NIAGARA control cohort… some may have had access to adjuvant IO to contribute to EFS? #ESMO26 @myESMO @OncoAlert https://t.co/K6ubio90xc
#JensBedke presents #Keynote866 trial cis/gem/pembro vs chemo/placebo in muscle invasive #bladdercancer — higher pathCR but misses on EFS and OS. @oncoalert @esmo #ESMO26 https://t.co/Wcbbi7dT7Z
Tian Zhang, MD, MHS, FASCO on CARE1
@AlbigesL with 1st deliverable for #CARE1 trial, PD-L1 stratified IO-IO vs IO-TKI in metastatic #kidneycancer. Local PD-L1 status correlated well w central review. Much more to come from this pragmatic trial! @oncoalert #ESMO26 @myESMO https://t.co/K2N2PMPjFt
Tian Zhang, MD, MHS, FASCO on KEYNOTE-564
@DrChoueiri w last, very last update of #Keynote564 pembrolizumab for adjuvant #kidneycancer. Ongoing overall survival benefit — even 7+ years out. @oncoalert #ESMO26 @myESMO https://t.co/RzNWvKHPuq
Tian Zhang, MD, MHS, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Learning about small cell lung from thoughtful discussant @StephenVLiu — new group of non smokers w small cell & w high clinical need for new treatments. Always mindful on patient access turning advances into impact. @oncoalert #ESMO26 @myESMO https://t.co/ICIlQB7mgz
#RandySweis showing data from EV-SG-zim in 1st line met #urothelialcancer — small sample size but high ORR 81% including 3 pts w CRs. Pushing depth of response for met UC. @oncoalert #ESMO26 @myESMO https://t.co/bCt3GBlOd9
Interesting ctDNA analysis from #EV304/B15 trial — ctDNA (+) groups w poor prognosis but EV-pembro works regardless of ctDNA status @myESMO #ESMO26 @oncoalert https://t.co/CoJhNDucjN
Congrats to my impactful mentor @Daniel_J_George, @OncLive Giant of cancer care for GU. Your work and mentees that you’ve supported thru the years have tremendous ripple power. Thank you for your time, effort, wisdom, and energy through the years. @OncoAlert #ASCO26 @ASCO https://t.co/LxLbttDfxl https://t.co/1J54epeaMR
Looking forward to joining the @OncBrothers & dear friends @apolo_andrea @montypal for this #ASCO26 adjacent discussion on Sat evening! https://t.co/DxLNicgAfJ
Industry Payments
CMS Open Payments · 2025 general payments
$25,345 across 47 payments